Does symmetric dimethylarginine rise as glomerular filtration declines and help assess kidney filtration alongside eGFR?

Symmetric dimethylarginine (SDMA) is a filtration-linked circulating marker: as kidney filtration falls, SDMA generally accumulates because renal clearance is its principal elimination route. For a 64-year-old woman, its interpretation should remain individualized and anchored to standard eGFR assessment.

Clinical evidence

• A meta-analysis of 18 studies (n=2,136) found strong associations between SDMA and inulin-measured clearance (r=0.85, 95% CI 0.76–0.91) and clearance-based GFR estimates (r=0.77, 95% CI 0.65–0.85).
• In 1,407 healthy middle-aged adults in the prospective RENIS cohort, SDMA correlated inversely with iohexol-measured GFR (r=−0.43).
• In CKD, renal plasma clearance reportedly fell about 56% from eGFR >90 to 30–59 mL/min/1.73 m², accompanied by higher SDMA concentrations.
• eGFR remains the clinical foundation: KDIGO recommends creatinine-based eGFR initially, creatinine–cystatin C eGFR when greater accuracy is needed, and measured GFR for decisions requiring high precision.

Mechanistic and prognostic context

• Reduced glomerular filtration and renal clearance promote SDMA retention. However, hepatic uptake/handling, AGXT2-mediated metabolism, inflammation, age, sex, and assay variation can affect measured levels.
• In CARE FOR HOMe (528 non-dialysis CKD G2–G4 participants), high-tertile SDMA was independently associated with CKD progression and incident atherosclerotic cardiovascular events. These are prognostic associations, not evidence that SDMA causes either outcome.

Clinical interpretation

• SDMA can provide complementary context when filtration assessment is uncertain, particularly because it is less dependent on muscle mass than creatinine.
• It should not replace guideline-recommended eGFR methods: correlation with measured GFR does not establish improved diagnostic classification, management, or outcomes when SDMA is added.

Bottom line

• The claim is supported: SDMA reliably rises with declining filtration and can be used alongside eGFR as an adjunctive marker, but eGFR—often refined with cystatin C or measured GFR—remains the primary basis for clinical kidney-function assessment.